跳至主要内容
临床试验/NCT01511835
NCT01511835Unknown4 期

Efficacy of Myo-inositol in Preventing Gestational Diabetes in High-risk Pregnant Women

AGUNCO Obstetrics and Gynecology Centre1 个研究点 分布在 1 个国家开始时间: 2012年1月19日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
发起方
试验地点
1
主要终点
OGTT

研究概览

简要总结

The aim of this study is to evaluate the efficacy of myo-inositol in preventing gestational diabetes in high risk pregnant women.

研究设计

研究类型
Interventional

入排标准

年龄范围
20 Years 至 45 Years(Adult)
性别
Female
接受健康志愿者

入选标准

  • 60 women in their first trimester of pregnancy affected by one or more of the following risk factors:
  • Glycemia levels > 92 mg/dl
  • BMI > 30
  • At least a parent or a brother (or sister)affected by diabetes
  • Pre-existing pregnancy with gestational diabetes

排除标准

  • Pregnant women affected by pregestational diabetes
  • Twin pregnancy
  • Patients affected by pre-existing diseases in pregnancy (diabetes excluded)
  • Patients affected by chronic disorders

研究组 & 干预措施

Myo-inositol powder

Experimental

干预措施: inositol + folic acid (Dietary Supplement)

Myo-inositol soft gel capsules

Experimental

干预措施: inositol + folic acid (Dietary Supplement)

Folic acid

Placebo Comparator

干预措施: Folic Acid (Drug)

结局指标

主要结局

OGTT

The diagnostic 75g oral glucose tolerance test (OGTT) is performed between 24 and 28 weeks of gestation.

次要结局

  • Number of pregnant women with gestational diabetes
  • Number of pregnant women requiring insulin treatment
  • Weight gain at the end of pregnancy
  • Number of newborn infants whose weight is more than 4000 g
  • Number of newborn infants requiring Neonatal Intensive Care (NIC)

研究者

发起方
AGUNCO Obstetrics and Gynecology Centre
申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验